Early Onset and Progression of Left Ventricular Remodeling After Alcohol Septal Ablation in Hypertrophic Obstructive Cardiomyopathy

Background—Alcohol septal ablation (ASA) reduces left ventricular outflow tract (LVOT) pressure gradient in patients with hypertrophic obstructive cardiomyopathy (HOCM), which leads to left ventricular remodeling. We sought to describe the early to midterm changes and modulating factors of the remodeling process using cardiac MRI (CMR). Methods and Results—CMR was performed at baseline and 1 and 6 months after ASA in 29 patients with HOCM (age 52±16 years). Contrast-enhanced CMR showed no infarct-related hyperenhancement outside the target septal area. Septal mass decreased from 75±23 g at baseline to 68±22 and 58±19 g (P<0.001) at 1- and 6-month follow-up, respectively. Remote, nonseptal mass decreased from 141±41 to 132±40 and 111±27 g (P<0.001), respectively. Analysis of temporal trends revealed that septal mass reduction was positively associated with contrast-enhanced infarct size and transmural or left-sided septal infarct location at both 1 and 6 months. Remote mass reduction was associated with infarct location at 6 months but not with contrast-enhanced infarct size. By linear regression analysis, percentage remote mass reduction correlated significantly with LVOT gradient reduction at 6-month follow-up (P=0.03). Conclusions—Left ventricular remodeling after ASA occurs early and progresses on midterm follow-up, modulated by CMR infarct size and location. Remote mass reduction is associated with infarct location and correlates with reduction of the LVOT pressure gradient. Thus, myocardial hypertrophy in HOCM is, at least in part, afterload dependent and reversible and is not exclusively caused by the genetic disorder.

[1]  W. Schill Applied Longitudinal Data Analysis for Epidemiology: A Practical Guide. , 2004 .

[2]  A. van Rossum,et al.  Myocardial infarction after percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy: evaluation by contrast-enhanced magnetic resonance imaging. , 2004, Journal of the American College of Cardiology.

[3]  R. Kim,et al.  How we perform delayed enhancement imaging. , 2003, Journal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance.

[4]  Mario J. Garcia,et al.  Comparison of left ventricular diastolic function in obstructive hypertrophic cardiomyopathy in patients undergoing percutaneous septal alcohol ablation versus surgical myotomy/myectomy. , 2003, The American journal of cardiology.

[5]  J. Veselka,et al.  Early remodelling of left ventricle and improvement of myocardial performance in patients after percutaneous transluminal septal myocardial ablation for hypertrophic obstructive cardiomyopathy. , 2003, International journal of cardiology.

[6]  Dudley J Pennell,et al.  Assessment of Left Ventricular Mass by Cardiovascular Magnetic Resonance , 2002, Hypertension.

[7]  N. Smedira,et al.  Outcome of patients with hypertrophic obstructive cardiomyopathy after percutaneous transluminal septal myocardial ablation and septal myectomy surgery. , 2002, Journal of the American College of Cardiology.

[8]  U. Sigwart,et al.  New concepts in hypertrophic cardiomyopathies, part II. , 2001, Circulation.

[9]  RobertRoberts,et al.  New Concepts in Hypertrophic Cardiomyopathies, Part II , 2001 .

[10]  A. Knez,et al.  Pressure-guided nonsurgical myocardial reduction induced by small septal infarctions in hypertrophic obstructive cardiomyopathy. , 2001, Journal of the American College of Cardiology.

[11]  J. Plana,et al.  Efficacy of nonsurgical septal reduction therapy in symptomatic patients with obstructive hypertrophic cardiomyopathy and provocable gradients. , 2001, The American journal of cardiology.

[12]  R. Kim,et al.  Visualization of presence, location, and transmural extent of healed Q-wave and non–Q-wave myocardial infarction , 2001 .

[13]  M. Entman,et al.  Decreased Expression of Tumor Necrosis Factor-&agr; and Regression of Hypertrophy After Nonsurgical Septal Reduction Therapy for Patients With Hypertrophic Obstructive Cardiomyopathy , 2001, Circulation.

[14]  S. Nagueh,et al.  Regression of Left Ventricular Hypertrophy After Nonsurgical Septal Reduction Therapy for Hypertrophic Obstructive Cardiomyopathy , 2001, Circulation.

[15]  Edwin Wu,et al.  Visualisation of presence, location, and transmural extent of healed Q-wave and non-Q-wave myocardial infarction , 2001, The Lancet.

[16]  J. K. Dunn,et al.  Nonsurgical septal reduction therapy for hypertrophic obstructive cardiomyopathy: one-year follow-up. , 2000, Journal of the American College of Cardiology.

[17]  J. Schulz-Menger,et al.  The value of magnetic resonance imaging of the left ventricular outflow tract in patients with hypertrophic obstructive cardiomyopathy after septal artery embolization. , 2000, Circulation.

[18]  L. Faber,et al.  Percutaneous transluminal septal myocardial ablation for hypertrophic obstructive cardiomyopathy: long term follow up of the first series of 25 patients , 2000, Heart.

[19]  A. Marian Pathogenesis of diverse clinical and pathological phenotypes in hypertrophic cardiomyopathy , 2000, The Lancet.

[20]  M. Henein,et al.  Electromechanical left ventricular behavior after nonsurgical septal reduction in patients with hypertrophic obstructive cardiomyopathy. , 1999, Journal of the American College of Cardiology.

[21]  S. Nagueh,et al.  Changes in left ventricular diastolic function 6 months after nonsurgical septal reduction therapy for hypertrophic obstructive cardiomyopathy. , 1999, Circulation.

[22]  U. Gleichmann,et al.  Percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy: results with respect to intraprocedural myocardial contrast echocardiography. , 1998, Circulation.

[23]  M. Verani,et al.  Echocardiography-guided ethanol septal reduction for hypertrophic obstructive cardiomyopathy. , 1998, Circulation.

[24]  D. Fassbender,et al.  Percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy: acute results and 3-month follow-up in 25 patients. , 1998, Journal of the American College of Cardiology.

[25]  L. Fananapazir,et al.  Therapeutic options in patients with obstructive hypertrophic cardiomyopathy and severe drug-refractory symptoms. , 1998, Journal of the American College of Cardiology.

[26]  B. Everitt,et al.  Analysis of longitudinal data , 1998, British Journal of Psychiatry.

[27]  D. Harrington,et al.  Nonsurgical septal reduction for hypertrophic obstructive cardiomyopathy: outcome in the first series of patients. , 1997, Circulation.

[28]  U. Sigwart Non-surgical myocardial reduction for hypertrophic obstructive cardiomyopathy , 1995, The Lancet.

[29]  O. Henriksen,et al.  Reproducibility of cardiac volume measurements including left ventricular mass determined by MRI. , 1993, Clinical physiology.

[30]  Tapabrata Maiti,et al.  Analysis of Longitudinal Data (2nd ed.) (Book) , 2004 .

[31]  O. Simonetti,et al.  An improved MR imaging technique for the visualization of myocardial infarction. , 2001, Radiology.